Drug Profile
Melanoma vaccine - Sanofi
Alternative Names: Ad2CMV-gp100; Ad2CMV-MART1Latest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator Genzyme Corporation
- Developer Sanofi
- Class Cancer vaccines
- Mechanism of Action Immunostimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Malignant melanoma
Most Recent Events
- 04 May 2006 No development reported - Phase-II for Malignant melanoma in USA (Intradermal)
- 29 Jul 2003 Genzyme General, Genzyme Biosurgery and Genzyme Molecular Oncology are now called Genzyme Corporation
- 03 Jul 2003 Data from a media release have been added to the adverse events and Cancer therapeutic trials sections